Page 134 - MI-2-2

Microbes & Immunity

COMMUNICATION
C Mab-21: A novel anti-human CCR8
8
monoclonal antibody for flow cytometry

†
†
†
Haruto Yamamoto , Yu Kaneko , Tomohiro Tanaka , Guanjie Li ,
Hiroyuki Suzuki* , Mika K. Kaneko , and Yukinari Kato*
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1,
Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan
(This article belongs to the Special Issue: Immunomodulation and Antitumor Strategies in the Tumor
Microenvironment)

Abstract

C-C motif chemokine receptor-8 (CCR8) belongs to class A of G protein-coupled
receptors. CCR8 interacts with the specific chemokine ligand CCL1/I-309 in humans,
which is produced by various cells, including tumor-associated macrophages and
regulatory T cells (Treg). CCR8 is highly expressed on Treg and T-helper 2 cells
recruited to the inflammation site and is implicated in allergy, asthma, and cancer
† These authors contributed equally progression. CCR8 Treg cells have been suggested an important regulator in the
+
to this work. immunosuppressive tumor microenvironment. Therefore, it has been proposed for
*Corresponding authors:
Hiroyuki Suzuki use in the development of sensitive monoclonal antibodies targeting CCR8. This
(hiroyuki.suzuki.b4@tohoku.ac.jp) study developed a specific mAb for human CCR8 (hCCR8), which is useful for flow
Yukinari Kato cytometry by employing the Cell-Based Immunization and Screening (CBIS) method.
(yukinari.kato.e6@tohoku.ac.jp) The established anti-hCCR8 mAb (C Mab-21; mouse IgM, kappa) demonstrated
8
Citation: Yamamoto H, Kaneko Y, reactivity with hCCR8-overexpressed Chinese hamster ovary-K1 (CHO/hCCR8)
Tanaka T, et al. C Mab-21: A novel cells, TALL-1 (human adult acute T-lymphoblastic leukemia), CCRF-HSB2 (human
8
anti-human CCR8 monoclonal
antibody for flow cytometry. T-lymphoblastic leukemia), and natural killer cells expressing endogenous hCCR8, as
Microbes & Immunity. 2025; confirmed by flow cytometry. Furthermore, EC values of C Mab-21 for CHO/hCCR8
50
8
2(2):126-136. and TALL-1 were determined as 6.5 × 10 M and 2.0 × 10 M, respectively. C Mab-
−8
−8
doi: 10.36922/mi.4661 8
21, established by the CBIS method, provides a useful tool for analyzing the hCCR8-
Received: August 26, 2024 related biological response using flow cytometry.
Revised: November 13, 2024
Accepted: December 2, 2024 Keywords: CCR8; CBIS method; Monoclonal antibody; Flow cytometry
Published online: December 16,
2024
Copyright: © 2024 Author(s).
This is an Open-Access article 1. Introduction
distributed under the terms of the
Creative Commons Attribution Targeting immune checkpoint has become an effective and powerful strategy for
License, permitting distribution, and cancer therapy. In particular, the development of antibody drugs targeting immune
1-4
reproduction in any medium, which
provided that the original work is checkpoint molecules, such as programmed-cell death-1 (PD-1), cytotoxic T
properly cited. lymphocyte antigen 4 (CTLA-4), and PD-1 ligand 1 (PD-L1), has achieved remarkable
5-7
Publisher’s Note: AccScience therapeutic results. PD-1 inhibits the excessive activation of conventional T
Publishing remains neutral with cells by suppressing costimulatory signaling and renders them dysfunctional or
regard to jurisdictional claims in 8
published maps and institutional exhausted. PD-1 and CTLA-4 are also expressed in regulatory T cells (Treg), one
9
affiliations. of the immunosuppresses in the tumor microenvironment (TME). Inhibition of

Volume 2 Issue 2 (2025) 126 doi: 10.36922/mi.4661